Ceftriaxone-induced hemolysis
Authors:
Open Access
- 1 January 2013
- journal article
- research article
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 45 (5) , 530-531
Abstract
Immune hemolytic anemia is a rare adverse effect of ceftriaxone, a third-generation cephalosporin, which is a commonly used antibiotic. We describe a 60-years-old lady, a case of community-acquired pneumonia, who developed severe hemolysis after the first dose of ceftriaxone. Her hemoglobin dropped from 9.6 g /dl to 5.5 g /dl. However, she improved after discontinuation of the drug and blood transfusion. This report serves as a reminder to medical fraternity that life-threatening hemolysis can rarely follow administration of ceftriaxone.Keywords
This publication has 6 references indexed in Scilit:
- Pathology Consultation on Drug-Induced Hemolytic AnemiaAmerican Journal of Clinical Pathology, 2011
- Immune hemolytic anemia associated with drug therapyBlood Reviews, 2010
- The Changing Spectrum of Drug-Induced Immune Hemolytic AnemiaSeminars in Hematology, 2005
- Cephalosporin AllergyNew England Journal of Medicine, 2001
- A fatal case of ceftriaxone (Rocephin)‐induced hemolytic anemia associated with intravascular immune hemolysisTransfusion, 1991
- IMMUNOGENICITY OF CEPHALOSPORIN DERIVATIVES AND THEIR CROSS-REACTION WITH PENICILLIN1966